KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Equity Average (2020 - 2025)

Historic Equity Average for Royalty Pharma (RPRX) over the last 6 years, with Q4 2025 value amounting to $9.7 billion.

  • Royalty Pharma's Equity Average fell 614.07% to $9.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $9.7 billion, marking a year-over-year decrease of 614.07%. This contributed to the annual value of $10.0 billion for FY2025, which is 180.82% down from last year.
  • According to the latest figures from Q4 2025, Royalty Pharma's Equity Average is $9.7 billion, which was down 614.07% from $9.6 billion recorded in Q3 2025.
  • Over the past 5 years, Royalty Pharma's Equity Average peaked at $10.4 billion during Q3 2022, and registered a low of $9.6 billion during Q3 2025.
  • In the last 5 years, Royalty Pharma's Equity Average had a median value of $10.0 billion in 2022 and averaged $10.0 billion.
  • Per our database at Business Quant, Royalty Pharma's Equity Average skyrocketed by 4832.12% in 2021 and then crashed by 684.67% in 2023.
  • Quarter analysis of 5 years shows Royalty Pharma's Equity Average stood at $10.3 billion in 2021, then dropped by 3.36% to $10.0 billion in 2022, then dropped by 1.37% to $9.8 billion in 2023, then increased by 4.74% to $10.3 billion in 2024, then dropped by 6.14% to $9.7 billion in 2025.
  • Its last three reported values are $9.7 billion in Q4 2025, $9.6 billion for Q3 2025, and $9.6 billion during Q2 2025.